{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T01:59:49Z","timestamp":1775872789520,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,15]]},"DOI":"10.7759\/cureus.62429","type":"journal-article","created":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T13:42:10Z","timestamp":1718458930000},"source":"Crossref","is-referenced-by-count":7,"title":["Rabies Vaccine for Prophylaxis and Treatment of Rabies: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Alan D","family":"Kaye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique  M","family":"Perilloux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Field","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cody A","family":"Orvin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spencer  C","family":"Zaheri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William C","family":"Upshaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raju","family":"Behara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasina Q","family":"Parker-Actlis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam M","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahab","family":"Ahmadzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahar","family":"Shekoohi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giustino","family":"Varrassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Rabies","author":"Koury R","year":"2023","unstructured":"Koury R, Warrington SJ. Rabies. StatPearls. StatPearls, Treasure Island, FL; 2023."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11040756","article-title":"Developments in rabies vaccines: the path traversed from Pasteur to the modern era of immunization","volume":"11","author":"Natesan K","year":"2023","unstructured":"Natesan K, Isloor S, Vinayagamurthy B, Ramakrishnaiah S, Doddamane R, Fooks AR. Developments in rabies vaccines: the path traversed from Pasteur to the modern era of immunization. Vaccines (Basel). 2023, 11:756. 10.3390\/vaccines11040756","journal-title":"Vaccines (Basel)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00705-016-3128-9","article-title":"Rabies vaccine development by expression of recombinant viral glycoprotein","volume":"162","author":"Astray RM","year":"2017","unstructured":"Astray RM, Jorge SA, Pereira CA. Rabies vaccine development by expression of recombinant viral glycoprotein. Arch Virol. 2017, 162:323-32. 10.1007\/s00705-016-3128-9","journal-title":"Arch Virol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijvsm.2018.05.001","article-title":"Advances in rabies prophylaxis and treatment with emphasis on immunoresponse mechanisms","volume":"6","author":"El-Sayed A","year":"2018","unstructured":"El-Sayed A. Advances in rabies prophylaxis and treatment with emphasis on immunoresponse mechanisms. Int J Vet Sci Med. 2018, 6:8-15. 10.1016\/j.ijvsm.2018.05.001","journal-title":"Int J Vet Sci Med"},{"key":"ref5","article-title":"Development in immunoprophylaxis against rabies for animals and humans","volume":"2","author":"Nandi S","year":"2010","unstructured":"Nandi S, Kumar M. Development in immunoprophylaxis against rabies for animals and humans. Avicenna J Med Biotechnol. 2010, 2:3-21.","journal-title":"Avicenna J Med Biotechnol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/s1286-4579(03)00075-3","article-title":"Louis Pasteur (1822-1895)","volume":"5","author":"Bordenave G","year":"2003","unstructured":"Bordenave G. Louis Pasteur (1822-1895). Microbes Infect. 2003, 5:553-60. 10.1016\/s1286-4579(03)00075-3","journal-title":"Microbes Infect"},{"key":"ref7","article-title":"Human rabies, with special reference to virus distribution and titer","volume":"20","author":"Leach CN","year":"194011","unstructured":"Leach CN, Johnson HN. Human rabies, with special reference to virus distribution and titer. Am J Trop Med Hyg. 194011, 20:335-40.","journal-title":"Am J Trop Med Hyg"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1201\/9780203736371","article-title":"The Natural History of Rabies","author":"Baer GM","year":"1991","unstructured":"Baer GM. The Natural History of Rabies. Routledge, New York; 1991. 10.1201\/9780203736371"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(02)00287-6","article-title":"Rabies re-examined","volume":"2","author":"Rupprecht CE","year":"2002","unstructured":"Rupprecht CE, Hanlon CA, Hemachudha T. Rabies re-examined. Lancet Infect Dis. 2002, 2:327-43. 10.1016\/s1473-3099(02)00287-6","journal-title":"Lancet Infect Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/4518163","article-title":"Evaluation of different stabilizers and inactivating compounds for the enhancement of vero cell rabies vaccine stability and immunogenicity: in vitro study","volume":"2019","author":"Olayan E","year":"2019","unstructured":"Olayan E, El-Khadragy M, Mohamed AF, Mohamed AK, Shebl RI, Yehia HM. Evaluation of different stabilizers and inactivating compounds for the enhancement of vero cell rabies vaccine stability and immunogenicity: in vitro study. Biomed Res Int. 2019, 2019:4518163. 10.1155\/2019\/4518163","journal-title":"Biomed Res Int"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4103\/0974-777X.77299","article-title":"Fundamentals of vaccine immunology","volume":"3","author":"Clem AS","year":"2011","unstructured":"Clem AS. Fundamentals of vaccine immunology. J Glob Infect Dis. 2011, 3:73-8. 10.4103\/0974-777X.77299","journal-title":"J Glob Infect Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0008142","article-title":"Inactivated rabies vaccines: standardization of an in vitro\u00a0assay for residual viable virus detection","volume":"14","author":"Moreira BL","year":"2020","unstructured":"Moreira BL, Gimenez AP, Inagaki JM, Raboni SM. Inactivated rabies vaccines: standardization of an in vitro\u00a0assay for residual viable virus detection. PLoS Negl Trop Dis. 2020, 14:e0008142. 10.1371\/journal.pntd.0008142","journal-title":"PLoS Negl Trop Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2012.04592.x","article-title":"Developments in rabies vaccines","volume":"169","author":"Hicks DJ","year":"2012","unstructured":"Hicks DJ, Fooks AR, Johnson N. Developments in rabies vaccines. Clin Exp Immunol. 2012, 169:199-204. 10.1111\/j.1365-2249.2012.04592.x","journal-title":"Clin Exp Immunol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.7774\/cevr.2013.2.1.19","article-title":"The present and future of rabies vaccine in animals","volume":"2","author":"Yang DK","year":"2013","unstructured":"Yang DK, Kim HH, Lee KW, Song JY. The present and future of rabies vaccine in animals. Clin Exp Vaccine Res. 2013, 2:19-25. 10.7774\/cevr.2013.2.1.19","journal-title":"Clin Exp Vaccine Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.00481","article-title":"Amino acid mutation in position 349 of glycoprotein affect the pathogenicity of rabies virus","volume":"11","author":"Luo J","year":"2020","unstructured":"Luo J, Zhang B, Wu Y, Guo X. Amino acid mutation in position 349 of glycoprotein affect the pathogenicity of rabies virus. Front Microbiol. 2020, 11:481. 10.3389\/fmicb.2020.00481","journal-title":"Front Microbiol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/v14010155","article-title":"Review of oral rabies vaccination of dogs and its application in India","volume":"14","author":"Yale G","year":"2022","unstructured":"Yale G, Lopes M, Isloor S, et al.. Review of oral rabies vaccination of dogs and its application in India. Viruses. 2022, 14:155. 10.3390\/v14010155","journal-title":"Viruses"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2015.06.011","article-title":"Genetically modified rabies virus ERA strain is safe and induces long-lasting protective immune response in dogs after oral vaccination","volume":"121","author":"Shuai L","year":"2015","unstructured":"Shuai L, Feng N, Wang X, et al.. Genetically modified rabies virus ERA strain is safe and induces long-lasting protective immune response in dogs after oral vaccination. Antiviral Res. 2015, 121:9-15. 10.1016\/j.antiviral.2015.06.011","journal-title":"Antiviral Res"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.08.018","article-title":"Could live attenuated vaccines better control COVID-19?","volume":"39","author":"Okamura S","year":"2021","unstructured":"Okamura S, Ebina H. Could live attenuated vaccines better control COVID-19?. Vaccine. 2021, 39:5719-26. 10.1016\/j.vaccine.2021.08.018","journal-title":"Vaccine"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3201\/eid2612.201266","article-title":"Role of oral rabies vaccines in the elimination of dog-mediated human rabies deaths","volume":"26","author":"Wallace RM","year":"2020","unstructured":"Wallace RM, Cliquet F, Fehlner-Gardiner C, et al.. Role of oral rabies vaccines in the elimination of dog-mediated human rabies deaths. Emerg Infect Dis. 2020, 26:1-9. 10.3201\/eid2612.201266","journal-title":"Emerg Infect Dis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.81.22.7194","article-title":"Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene","volume":"81","author":"Wiktor TJ","year":"1984","unstructured":"Wiktor TJ, Macfarlan RI, Reagan KJ, et al.. Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene. Proc Natl Acad Sci U S A. 1984, 81:7194-8. 10.1073\/pnas.81.22.7194","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)92027-d","article-title":"Immunisation with canarypox virus expressing rabies glycoprotein","volume":"13","author":"Cadoz M","year":"1992","unstructured":"Cadoz M, Meignier B, Plotkin S, et al.. Immunisation with canarypox virus expressing rabies glycoprotein. Lancet. 1992, 13:1429-32. 10.1016\/0140-6736(92)92027-d","journal-title":"Lancet"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02470-12","article-title":"A new rabies vaccine based on a recombinant ORF virus (parapoxvirus) expressing the rabies virus glycoprotein","volume":"87","author":"Amann R","year":"2013","unstructured":"Amann R, Rohde J, Wulle U, Conlee D, Raue R, Martinon O, Rziha HJ. A new rabies vaccine based on a recombinant ORF virus (parapoxvirus) expressing the rabies virus glycoprotein. J Virol. 2013, 87:1618-30. 10.1128\/JVI.02470-12","journal-title":"J Virol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.53.3.926-934.1985","article-title":"Rabies virulence: effect on pathogenicity and sequence characterization of rabies virus mutations affecting antigenic site III of the glycoprotein","volume":"53","author":"Seif I","year":"1985","unstructured":"Seif I, Coulon P, Rollin PE, Flamand A. Rabies virulence: effect on pathogenicity and sequence characterization of rabies virus mutations affecting antigenic site III of the glycoprotein. J Virol. 1985, 53:926-34. 10.1128\/JVI.53.3.926-934.1985","journal-title":"J Virol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2019.12.012","article-title":"Structural analysis of rabies virus glycoprotein reveals pH-dependent conformational changes and interactions with a neutralizing antibody","volume":"27","author":"Yang F","year":"2020","unstructured":"Yang F, Lin S, Ye F, et al.. Structural analysis of rabies virus glycoprotein reveals pH-dependent conformational changes and interactions with a neutralizing antibody. Cell Host Microbe. 2020, 27:441-453.e7. 10.1016\/j.chom.2019.12.012","journal-title":"Cell Host Microbe"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.77.20.10780-10789.2003","article-title":"Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier","volume":"77","author":"Xiang ZQ","year":"2003","unstructured":"Xiang ZQ, Gao GP, Reyes-Sandoval A, Li Y, Wilson JM, Ertl HC. Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. J Virol. 2003, 77:10780-9. 10.1128\/jvi.77.20.10780-10789.2003","journal-title":"J Virol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2011.12.005","article-title":"Current rabies vaccines and prophylaxis schedules: preventing rabies before and after exposure","volume":"10","author":"Warrell MJ","year":"2012","unstructured":"Warrell MJ. Current rabies vaccines and prophylaxis schedules: preventing rabies before and after exposure. Travel Med Infect Dis. 2012, 10:1-15. 10.1016\/j.tmaid.2011.12.005","journal-title":"Travel Med Infect Dis"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.16.173039","article-title":"Pre-exposure rabies prophylaxis: a systematic review","volume":"95","author":"Kessels JA","year":"2017","unstructured":"Kessels JA, Recuenco S, Navarro-Vela AM, et al.. Pre-exposure rabies prophylaxis: a systematic review. Bull World Health Organ. 2017, 95:210-219C. 10.2471\/BLT.16.173039","journal-title":"Bull World Health Organ"},{"key":"ref28","article-title":"Safety, immunogenicity and clinical efficacy of post exposure prophylaxis in confirmed rabies exposures","volume":"1","author":"Haradanahalli SR","year":"2016","unstructured":"Haradanahalli SR, Krishna C, Kumar DP, Siddareddy I, Annadani RR. Safety, immunogenicity and clinical efficacy of post exposure prophylaxis in confirmed rabies exposures. Glob Vaccines Immunol. 2016, 1:56-9.","journal-title":"Glob Vaccines Immunol"},{"key":"ref29","article-title":"The present status of rabies vaccine development and clinical experience with rabies vaccine","volume":"19","author":"Roumiantzeff M","year":"1988","unstructured":"Roumiantzeff M. The present status of rabies vaccine development and clinical experience with rabies vaccine. Southeast Asian J Trop Med Public Health. 1988, 19:549-61.","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.2147\/CPAA.S166454","article-title":"Safety and neutralizing rabies antibody in healthy subjects given a single dose of rabies immune globulin caprylate\/chromatography purified","volume":"10","author":"Hanna K","year":"2018","unstructured":"Hanna K, Cruz MC, Mondou E, Corsi E, Vandeberg P. Safety and neutralizing rabies antibody in healthy subjects given a single dose of rabies immune globulin caprylate\/chromatography purified. Clin Pharmacol. 2018, 10:79-88. 10.2147\/CPAA.S166454","journal-title":"Clin Pharmacol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.04.003","article-title":"The effect of combined drugs therapy on the course of clinical rabies infection in a murine model","volume":"37","author":"Smreczak M","year":"2019","unstructured":"Smreczak M, Or\u0142owska A, Marzec A, et al.. The effect of combined drugs therapy on the course of clinical rabies infection in a murine model. Vaccine. 2019, 37:4701-9. 10.1016\/j.vaccine.2018.04.003","journal-title":"Vaccine"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00429","article-title":"Toll-like receptor 7 enhances rabies virus-induced humoral immunity by facilitating the formation of germinal centers","volume":"10","author":"Luo Z","year":"2019","unstructured":"Luo Z, Li Y, Zhou M, et al.. Toll-like receptor 7 enhances rabies virus-induced humoral immunity by facilitating the formation of germinal centers. Front Immunol. 2019, 10:429. 10.3389\/fimmu.2019.00429","journal-title":"Front Immunol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.02.031","article-title":"Rabies virus-like particles expressed in HEK293 cells","volume":"32","author":"Fontana D","year":"2014","unstructured":"Fontana D, Kratje R, Etcheverrigaray M, Prieto C. Rabies virus-like particles expressed in HEK293 cells. Vaccine. 2014, 32:2799-804. 10.1016\/j.vaccine.2014.02.031","journal-title":"Vaccine"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1292\/jvms.13-0127","article-title":"Adeno-associated viruses serotype 2-mediated RNA interference efficiently inhibits rabies virus replication in vitro and in vivo","volume":"75","author":"Wu HX","year":"2013","unstructured":"Wu HX, Wang HL, Guo XF, et al.. Adeno-associated viruses serotype 2-mediated RNA interference efficiently inhibits rabies virus replication in vitro and in vivo. J Vet Med Sci. 2013, 75:1355-61. 10.1292\/jvms.13-0127","journal-title":"J Vet Med Sci"},{"key":"ref35","doi-asserted-by":"crossref","DOI":"10.9734\/AJRIMPS\/2018\/43202","article-title":"Eradication of rabies with mass parental vaccination, human post-exposure prophylaxis, and gene therapy: a systematic review","volume":"4","author":"Nelwan M","year":"2018","unstructured":"Nelwan M. Eradication of rabies with mass parental vaccination, human post-exposure prophylaxis, and gene therapy: a systematic review. Asian J Res Med Pharm Sci. 2018, 4:1-12.","journal-title":"Asian J Res Med Pharm Sci"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2026713","article-title":"Advances in the progress of monoclonal antibodies for rabies","volume":"18","author":"Fan L","year":"2022","unstructured":"Fan L, Zhang L, Li J, Zhu F. Advances in the progress of monoclonal antibodies for rabies. Hum Vaccin Immunother. 2022, 18:2026713. 10.1080\/21645515.2022.2026713","journal-title":"Hum Vaccin Immunother"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1136\/vr.g4996","article-title":"Rabies control and elimination: a test case for One Health","volume":"175","author":"Cleaveland S","year":"2014","unstructured":"Cleaveland S, Lankester F, Townsend S, Lembo T, Hampson K. Rabies control and elimination: a test case for One Health. Vet Rec. 2014, 175:188-93. 10.1136\/vr.g4996","journal-title":"Vet Rec"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.20506\/rst.38.1.2954","article-title":"Lessons for rabies control and elimination programmes: a decade of One Health experience from Bali, Indonesia","volume":"38","author":"Purwo Suseno P","year":"2019","unstructured":"Purwo Suseno P, Rysava K, Brum E, et al.. Lessons for rabies control and elimination programmes: a decade of One Health experience from Bali, Indonesia. Rev Sci Tech. 2019, 38:213-24. 10.20506\/rst.38.1.2954","journal-title":"Rev Sci Tech"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.4161\/hv.26264","article-title":"Making rabies prophylaxis more economical: immunogenicity and safety results from a preliminary study using a 2-1 intramuscular regimen in healthy volunteers","volume":"10","author":"Huang G","year":"2014","unstructured":"Huang G, Liu H, Tang Q, et al.. Making rabies prophylaxis more economical: immunogenicity and safety results from a preliminary study using a 2-1 intramuscular regimen in healthy volunteers. Hum Vaccin Immunother. 2014, 10:114-9. 10.4161\/hv.26264","journal-title":"Hum Vaccin Immunother"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268817002850","article-title":"Assessing the impact of public education on a preventable zoonotic disease: rabies","volume":"146","author":"Hasanov E","year":"2018","unstructured":"Hasanov E, Zeynalova S, Geleishvili M, et al.. Assessing the impact of public education on a preventable zoonotic disease: rabies. Epidemiol Infect. 2018, 146:227-35. 10.1017\/S0950268817002850","journal-title":"Epidemiol Infect"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/257103-rabies-vaccine-for-prophylaxis-and-treatment-of-rabies-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T13:42:14Z","timestamp":1718458934000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/257103-rabies-vaccine-for-prophylaxis-and-treatment-of-rabies-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,15]]},"references-count":40,"URL":"https:\/\/doi.org\/10.7759\/cureus.62429","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,15]]}}}